Kirill Dmitriev is the CEO of the Russian Direct Investment Fund – one of the world’s leading sovereign funds with a reserve capital of $10 billion under its management. Since the launch of the Sputnik V vaccine, developed by scientists from Moscow’s Gamaleya Center, Russia has seen immense interest and expressions of hope from many countries and has received requests for 1 billion doses.
However, it has also faced criticism and questions from some Western countries and companies, especially those developing their own vaccines—often based on technologies yet to be proven for safety and efficacy, such as mRNA or monkey adenoviral vector-based platforms. Following the publication of the results of the Phase 1 and Phase 2 clinical trials of Sputnik V in The Lancet, last week, we would like to address some issues that have been raised and ask a few questions of our own.
Continue reading https://on.rt.com/apvb